Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Henagliflozin for Liver Fibrosis in MASLD and T2DM
NCT06762223Phase 4Not yet recruiting
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of henagliflozin in metabolic dysfunction-associated steatotic liver disease (MASLD) and Liver Fibrosis (LF) (2 arms). Primary endpoint: Liver stiffness measurements (LSM) at 48 weeks. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
henagliflozin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT06762223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06762223.